

Amendments to the Claims:

This listing of claims will replace all prior versions.

1. (currently amended) A method of treating chronic obstructive pulmonary disease (COPD) in a subject, comprising detecting an elevated level of IFN- γ and/or IL-13 and administering an effective amount of an antibody which specifically binds to chemokine receptor 5 (CCR5) antagonist to a subject with elevated levels of IFN- γ and/or IL-13 as compared to normal levels, thereby treating said COPD.
2. (canceled)
3. (canceled)
4. (original) The method of claim 1, wherein said subject is a smoker with COPD.
5. (canceled)
6. (currently amended) The method of claim 1 claim 5, wherein said antibody specifically binds to CCR5.
7. (currently amended) The method of claim 1 claim 5, wherein said antibody binds to a mammalian CCR5.
8. (original) The method of claim 6, wherein the mammalian CCR5 is a human CCR5.
9. (currently amended) The method of claim 1 claim 5, wherein said antibody inhibits binding of one or more chemokines selected from the group consisting of MIP-1 α , MIP-1 β , and RANTES to the receptor.
10. (currently amended) The method of claim 1 claim 5, wherein said antibody inhibits one or more functions associated with binding of said one or more chemokines to the receptor.
11. (currently amended) The method of claim 1 claim 5, wherein the antibody is a monoclonal antibody.
12. (currently amended) The method of claim 1 claim 5, wherein the antibody is a chimeric antibody.
13. (currently amended) The method of claim 1 claim 5, wherein the antibody is a human antibody.
14. (currently amended) The method of claim 15, wherein the antibody is a humanized antibody.

15. (withdrawn/currently amended) The method of claim 1 ~~claim 5~~, wherein said antisense nucleic acid molecule is an isolated nucleic acid complementary to an isolated nucleic acid encoding said CCR5, or a fragment thereof.

16. (withdrawn/currently amended) The method of claim 1 ~~claim 5~~, wherein said ribozyme is an isolated enzymatic nucleic acid, which specifically cleaves mRNA transcribed from a nucleic acid encoding said CCR5, or a fragment thereof.

17. (previously presented) The method of claim 1, wherein said COPD is chronic bronchitis.

18. (withdrawn) A method of inhibiting apoptosis in a subject, comprising administering an effective amount of CCR5 antagonist to said subject.

19. (previously presented) The method of claim 1, wherein said COPD is emphysema.